Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400
ETON Stock | USD 13.53 0.79 6.20% |
About 54% of Eton Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Eton Pharmaceuticals stock suggests that some investors are interested at this time. Eton Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Eton Pharmaceuticals. Many technical investors use Eton Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Eton |
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle to achieve potential combined peak sales of more than 50 million annually -- Product has patent protection through 2043 - DEER PARK, Ill., April 30, 2024 -- Eton Pharmaceuticals, Inc , an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission
Read at finance.yahoo.com
Eton Pharmaceuticals Fundamental Analysis
We analyze Eton Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eton Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eton Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Eton Pharmaceuticals is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Eton Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eton Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Eton Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eton Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Eton Pharmaceuticals Related Equities
PASG | Passage Bio | 68.66 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
ELDN | Eledon Pharmaceuticals | 9.39 | ||||
GOSS | Gossamer Bio | 6.06 | ||||
TARS | Tarsus Pharmaceuticals | 3.17 | ||||
BDTX | Black Diamond | 3.11 | ||||
CNTB | Connect Biopharma | 2.91 | ||||
ALEC | Alector | 1.57 | ||||
TVTX | Travere Therapeutics | 0.59 | ||||
ABOS | Acumen Pharmaceuticals | 0.44 | ||||
NUVB | Nuvation Bio | 0.35 | ||||
CELC | Celcuity LLC | 0.39 | ||||
ALDX | Aldeyra | 0.81 | ||||
KRON | Kronos Bio | 1.04 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
INBX | Inhibrx | 2.37 | ||||
ELVN | Enliven Therapeutics | 4.05 | ||||
NVCT | Nuvectis Pharma | 4.55 |
Check out Eton Pharmaceuticals Hype Analysis, Eton Pharmaceuticals Correlation and Eton Pharmaceuticals Performance. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.